AVI BioPharma, Inc. 2011 Form 10-K Summary
Filing identity: The supplied filing is for AVI BioPharma, Inc., not Sarepta Therapeutics, Inc.; AVI later became Sarepta. The report covers the fiscal year ended December 31, 2011, including fourth-quarter results. Figures are in thousands except per-share data unless otherwise noted.
Business Context and Reporting Period
AVI was a development-stage biopharmaceutical company focused on RNA-based therapeutics for rare and infectious diseases. Its lead proprietary program was eteplirsen for Duchenne muscular dystrophy, in a fully enrolled Phase IIb trial. Infectious-disease programs included Ebola candidate AVI-6002, Marburg candidate AVI-6003, and influenza candidate AVI-7100, substantially funded by the U.S. Department of Defense.
- Eteplirsen Phase IIb Study 201 began in August 2011 with 12 participants; management expected results by the end of April 2012 and intended to begin a pivotal Phase III trial by the end of 2012.
- AVI had no approved products and generated no material commercial product revenue.
- Substantially all revenue came from U.S. government research contracts and grants.
Financial Results and Key Metrics
| Metric | 2011 | 2010 | Change |
|---|---|---|---|
| Revenue | $46.990 million | $29.420 million | Up 60% |
| Research and development expense | $66.862 million | $35.972 million | Up 86% |
| General and administrative expense | $16.055 million | $14.382 million | Up 12% |
| Operating loss | $(35.927) million | $(20.934) million | Loss widened |
| Net loss | $(2.318) million | $(32.177) million | Improved primarily from warrant revaluation |
| Basic and diluted loss per share | $(0.02) | $(0.29) | Improved |
| Cash used in operating activities | $(23.679) million | $(15.209) million | Use increased 56% |
| Cash and cash equivalents | $39.904 million | $33.589 million | Up $6.315 million |
| Working capital | $24.583 million | $(8.019) million | Improved |
| Shareholders’ equity | $31.017 million | $(2.817) million | Improved |
- Approximate operating margin was negative 76.5% in 2011, compared with negative 71.2% in 2010.
- Approximate reported net margin was negative 4.9% in 2011, compared with negative 109.4% in 2010; the comparison is distorted by non-cash warrant valuation changes.
- The $33.022 million gain from the change in fair value of warrant liabilities was the principal reason reported net loss was much smaller than operating loss. Warrant liabilities declined from $39.111 million to $5.446 million.
- Debt totaled $1.842 million, consisting of two loans bearing interest at 4.75% and maturing in February 2027; $85,000 was current.
- Contractual obligations totaled $20.738 million, including $15.971 million of operating leases, $1.842 million of long-term debt, and $2.925 million of purchase commitments.
Material Changes Versus the Prior Comparable Period
- Revenue increased $17.570 million, primarily from $42.875 million recognized under the July 2010 Ebola and Marburg contract, versus $9.822 million in 2010.
- Research and development expense increased $30.890 million, driven by Ebola and Marburg development, the DMD program, proprietary research, and manufacturing activities.
- Operating loss widened by $14.993 million despite higher revenue, reflecting substantially higher development spending.
- Operating cash burn increased by $8.470 million.
- Cash increased due primarily to a $32.1 million net equity offering completed in April 2011, which issued 23.0 million shares.
- The company reduced its workforce by 35 employees, or 28%, in December 2011 and recorded $1.145 million of restructuring charges; severance payments were expected to be completed by July 31, 2012.
- AVI-7100 influenza development was paused after the June 2011 government contract ended and unsuccessful submissions for additional DoD funding; the company was seeking DHHS or industry funding.
- Share count increased to 135.743 million outstanding at year-end from 112.352 million at year-end 2010. The company also had 29.205 million outstanding warrants and 14.506 million outstanding options.
Guidance, Outlook, Risks, and Unusual Items
- Management stated that cash and anticipated receipts under funded government contracts were expected to finance operations for at least the following 12 months, but also indicated that additional financing would likely be required.
- Under the July 2010 Ebola and Marburg agreement, approximately $126.5 million was available for current contract segments, of which $52.7 million had been recognized. If all options were exercised, total contract funding could reach $288.0 million, with $161.5 million remaining to be funded.
- Government funding is subject to appropriations, performance requirements, audits, and termination rights. A delay, reduction, or termination could materially impair liquidity and research programs.
- The company remained dependent on third-party manufacturers with limited PMO production capacity and had no internal commercial manufacturing capability.
- Clinical and regulatory risk remained high: no product had been approved, eteplirsen’s consistently effective dose had not been established, and the Ebola and Marburg programs relied on the uncertain FDA Animal Rule pathway.
- Prosensa-related European, Japanese, and U.S. patent rights could create infringement or commercialization risks for eteplirsen and other exon-skipping products.
- AVI received a NASDAQ minimum-bid-price deficiency notice in December 2011 but regained compliance in February 2012.
- The filing reported no material legal proceedings. Management and KPMG concluded that internal control over financial reporting was effective.
Most Important Facts for Investors to Verify
- Confirm the issuer identity and corporate continuity because the supplied filing is for AVI BioPharma rather than the company name in the request.
- Review subsequent clinical results for eteplirsen, including whether the Phase IIb readout supported a pivotal trial and eventual approval.
- Verify the continuation, funding, and option exercise status of the DoD Ebola and Marburg contract.
- Assess liquidity after the $23.7 million 2011 operating cash burn and determine the timing and terms of subsequent financing.
- Separate recurring operating performance from the $33.0 million non-cash warrant revaluation gain.
- Review dilution from outstanding warrants, options, and future equity financing requirements.
- Track the Prosensa patent disputes and any other intellectual-property claims affecting eteplirsen.
- Evaluate whether the paused influenza program obtained new government or commercial funding.